The beneficial effects that BACE2 inhibition exerts on β-cell mass and function in different models of T2D suggests that selective BACE2 inhibitors may be potentially a new path for the treatment of this disease [24]. This evidence concerns the gene BACE2 and type 2 diabetes mellitus.